Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
Condition(s):Pulmonary Adenosquamous CarcinomaLast Updated:November 8, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Pulmonary Adenosquamous CarcinomaLast Updated:November 8, 2023Recruiting
Condition(s):Adenosquamous Carcinoma of the PancreasLast Updated:January 31, 2024Recruiting
Condition(s):ESCC or Esophageal Adenosquamous CarcinomaLast Updated:August 29, 2022Recruiting
Condition(s):Pancreas CancerLast Updated:July 3, 2023Withdrawn
Condition(s):Adenocarcinoma of the Cervix; Adenosquamous Cell Carcinoma of the CervixLast Updated:November 2, 2018Terminated
Condition(s):Carcinoma, Squamous Cell; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell LungLast Updated:January 13, 2014Terminated
Condition(s):Carcinoma; Adenocarcinoma; Uterine Cervix Adenosquamous CarcinomaLast Updated:July 14, 2014Withdrawn
Condition(s):Pancreatic Adenosquamous Carcinoma; Resectable Pancreatic Adenocarcinoma; Pancreatic CancerLast Updated:February 20, 2024Recruiting
Condition(s):Cervix Carcinoma; Cervical Squamous Cell Carcinoma; Cervical Adenosquamous CarcinomaLast Updated:December 3, 2021Completed
Condition(s):Cervical Carcinoma; Adenocarcinoma; Adenosquamous CarcinomaLast Updated:March 25, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.